The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.
This study is open to males and females \> 18 years and \< 81 years with a clinical diagnosis of blepharospasm.
Study Type
OBSERVATIONAL
Enrollment
124
Merz Investigative Site #0007
Fountain Valley, California, United States
Merz Investigative Site # 0002
Sarasota, Florida, United States
Merz Investigative Site # 0001
Boston, Massachusetts, United States
Merz Investigative Site #003
Durham, North Carolina, United States
Botulinum Toxin Treatment Information
The following information for patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA, or onabotulinumtoxinA treatment is collected: (1) botulinum treatment information such as intervals for botulinum injections, physician's rationale for injection interval, overall experience with botulinum toxin injections (onset, maximum effect, decline of effect), current injection cycle experience (current satisfaction, satisfaction at maximum effect, and visual analog scale (VAS) of current health status); and (2) disability status using the Blepharospasm Disability Index (BSDI) and the Jankovic Rating Scale (JRS)
Time frame: This is a single, structured interview about experiences with Botulinum Toxins
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Merz Investigative Site # 0006
Columbus, Ohio, United States